Diligence memo · auto-generated · as of July 2, 2026
Lengo Therapeutics Ltd
Lengo Therapeutics Ltd looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Lengo Therapeutics Ltd operates in Pharma, based in NEW YORK.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Lengo Therapeutics Ltd has raised $7.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $7.0M on 2023-04-11.
Most recent recorded round closed around 2023-04-11.
Valuation (modeled)modeled
Provath models Lengo Therapeutics Ltd at approximately $62M (range $8.0M–$179M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.91× the median modeled value of Series A Pharma companies in 2022–2024 (24 peers) — value vs value, same stage and era. Within the normal band (91% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 3.2 yr ago; this sector typically re-raises about every 16 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 60% of Pharma peers (310 compared).
Modeled value ranks above 58% of those peers.
Closest niche peers: Carmine Therapeutics, Inc., Triomics, Inc., Spiral Therapeutics Inc, Convelo Therapeutics, Inc., ADvantage Therapeutics, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.